IRAS Project ID:	**215928**
REC Reference:	**16/LO/1827**
Short Study Title:	**Perioperative Quality Improvement Programme: Patient Study**
Date complete amendment submission received:	**21 October 2016**
Amendment No./ Sponsor Ref:	**1.0 12/10/16**
Amendment Date:	**21 October 2016**
Amendment Type:	**Substantial**

Thank you for submitting the above referenced amendment. I am pleased to confirm that this amendment has been submitted to the REC for ethical review. Please find attached a copy of the validation letter.

Categorisation of Amendment

In line with the UK Process for Handling UK Study Amendments I can confirm that this amendment has been categorised as:

- **Category A -** An amendment that has implications for, or affects, ALL participating NHS organisations

You should now provide this email, together with the amended documentation, to the research management support offices **and** local research teams at your participating NHS organisations in England.

If you have participating NHS organisations in Northern Ireland, Scotland and/or Wales, you should communicate directly with the relevant research teams to prepare them for implementing the amendment, as per the instructions below. You do not need to provide this email or your amended documentation to their research management support offices, as we will pass these to the relevant national coordinating functions who will do this on your behalf.

Subject to the three conditions below, you will be able to implement the amendment at your participating NHS organisations in England **35 days after you notify them of the amendment.** A template email to notify participating NHS organisations in England is provided here.

Subject to the same three conditions, you will be able to implement your amendment at participating NHS organisations in Northern Ireland, Scotland or Wales on 25 November 2016.

- You may not implement this amendment until and unless you receive all required regulatory approvals, including REC favourable opinion, (for participating organisations in England, this includes receiving confirmation of HRA Approval for the amendment). You should provide regulatory approvals to the research management support offices and local research teams at your participating NHS organisations in England, plus to local research teams at any participating NHS organisations in Northern Ireland, Scotland or Wales*.
- You may not implement this amendment at any participating NHS organisations which inform you within the 35 day period that they require additional time to consider the amendment, until they notify you that the considerations have been satisfactorily completed.
- You may not implement this amendment at any participating NHS organisation that informs you that it is no longer able to undertake this study.

Note: you may only implement changes described in the amendment notice or letter.

If you receive required regulatory approvals (for participating organisations in England, this includes confirmation that the amendment has been granted HRA Approval) after the 35 days have passed, you may then immediately implement this amendment at all participating NHS organisations that have not requested additional review time, or are no longer able to undertake this study.

There is no need for you to receive a letter of confirmation from the participating organisation that the amendment can be implemented, as the intended date of implementation is communicated through the above process. However, you may be able to implement this amendment ahead of the 35 day deadline, if all necessary regulatory approvals are in place and the participating organisation has confirmed that the amendment may be implemented ahead of the 35 day date.

* Where the study involves NHS organisations in Northern Ireland, Scotland or Wales, the HRA will forward regulatory approvals to the relevant national coordinating function to distribute to their research management support offices.

Participating NHS Organisations in England – Confirmation of Assessment Arrangements

- If this study has HRA Approval, this amendment may be implemented at participating NHS organisations in England once the conditions detailed in the categorisation section above have been met
- If this study is a pre-HRA Approval study, this amendment may be implemented at participating NHS organisations in England that have NHS Permission, once the conditions detailed in the categorisation section above have been met. For participating NHS organisations in England that do not have NHS Permission, these sites should be covered by HRA Approval before the amendment is implemented at them, please see below;
- If this study is awaiting HRA Approval, I have passed your amendment to my colleague in the assessment team and you should receive separate notification that the study has received HRA Approval, incorporating approval for this amendment.

Please do not hesitate to contact me if you require further information.

Kind regards

Wai

Mr Wai Yeung | Research Ethics Committee Assistant – 020 71048053
Mr Rajat Khullar | Research Ethics Committee Manager – 020 71048033
South East Coast – Surrey & London – City & East
Health Research Authority
Bristol HRA Centre, Level 3, Block B,
Whitefriars, Lewins Mead, Bristol BS1 2NT
HRA (Bristol Centre): 020 71048056 | www.hra.nhs.uk
IMPORTANT – **Click here** for details of significant changes to the REC booking and submission process

The HRA is keen to know your views on the service you received – our short feedback form is available **here**